|
April 1, 2013 - Med Opportunity Partners, LLC (“MEDOP”), a Greenwich CT-based private equity firm focused exclusively on the health care sector, announced today its acquisition of Ferro Pfanstiehl Laboratories, Inc., a global leader in cGMP carbohydrates and Active Pharmaceutical Ingredients (APIs), from Ferro Corporation. MEDOP, a strategic, operating-oriented investment firm, brings significant resources, pharmaceutical and biopharmaceutical relationships, and capital to fuel the Company’s growth.
|
|
Read more...
|
|
|
St. Louis, Missouri - September 27, 2010
Reliable
Biopharmaceutical Corporation ("RBC") today announced that David
Feldker will join RBC and become its CEO and President effective October
23, 2010, and join RBC's Board of Directors. David was previously Vice President SAFC at
Sigma-Aldrich Corp. with responsibility for the Active Pharmaceutical
Ingredient ("API") contract development and manufacturing segment.
|
|
Read more...
|
|
|
"Med Opportunity Partners Leads Purchase Of St. Louis Based Active Pharmaceutical Ingredient Manufacturer Reliable Biopharmaceutical Corporation"
Greenwich, CT, October 22nd, 2007 - Med Opportunity Partners LLC (MEDOP), a Greenwich CT-based operating oriented private equity firm, today announced the acquisition of Reliable Biopharmaceutical Corporation (RBC).
|
|
Read more...
|
|
|
News 
